Stephen graduated Princeton University with a Computer Science degree and is a passionate mushroom forager. He's excited to highlight psychedelic research especially as it relates to the field of mental health.
December 6, 2017
The Ibogaine Conversation Part 3 | What is the authentic Bwiti tradition? The answer I got was that this idea of authenticity is an odd idea. It’s a very Western idea. Bwiti considers itself as a culture that’s changing.
December 11, 2017
The Ibogaine Conversation Part 4 | The Western world cannot receive the benefits of iboga if they don’t try to understand and assimilate the traditional approach.
December 12, 2017
The Ibogaine Conversation Part 5 | Thomas Kingsley Brown, PhD, studied the long-term outcomes of people who received ibogaine for the treatment of opioid addiction. We talked about the results.
December 13, 2017
The Ibogaine Conversation Part 6 | My experience with heroin went from age 14 up to age 30, and taking ibogaine was as close to a miracle as I have ever experienced in my life.
December 18, 2017
The Ibogaine Conversation Part 7 | "Prescription is not about accessibility, by definition it’s about restriction. Unless we start to use psychedelics as a way to tear apart these structures and build new ones in their place, then I think it's all a revolving door."
December 19, 2017
The Ibogaine Conversation Part 8 | This is not a do-it-at-home type thing.
January 2, 2018
The Ibogaine Conversation Part 9 | Using ibogaine can be fatal if proper safety precautions aren’t taken.
January 3, 2018
The Ibogaine Conversation Part 10 | Unlike other psychedelic drugs, ibogaine is known to be potentially cardiotoxic. There are a number of fatalities associated with its use, and anyone considering working with it should be aware of the risks.
January 9, 2018
The Ibogaine Conversation Conclusion | The goal of this conversation was to provide a platform for a diverse range of perspectives on a single topic. Not everyone agrees, and that’s the point.
March 12, 2018
Meet some of the people on the front lines of global drug reform at The Commission on Narcotic Drugs in Vienna.